Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Propylene Glycol Toxicity Subject Of February NTP Meeting

This article was originally published in The Tan Sheet

Executive Summary

Consumers would have to ingest more than 15 g/kg of propylene glycol to experience a lethal effect, a National Toxicology Program Center for the Evaluation of Risks to Human Reproduction draft report estimates

You may also be interested in...



Minoxidil & dermatitis

Patients who suffer from allergic contact dermatitis due to treatment with topical minoxidil solution "should be advised to undergo patch testing to determine the causative allergen," researchers report in February Journal of the American Academy of Dermatology. Edward Friedman, et al., NYU School of Medicine, suggest patients could be sensitive to an agent in the solution other than minoxidil, such as propylene glycol, in which case "they should be given the option of formulations compounded with alternative solvents." Friedman et al. patch-tested 11 individuals with alopecia; nine showed a positive allergic reaction to propylene glycol, while only four reacted to minoxidil...

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094917

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel